Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 10/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 17/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 14/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 10/20 | 0.43 |
| ▸ | HDAC7 | Q8WUI4 | 10/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 10/20 | 0.43 |
| ▸ | HDAC10 | Q969S8 | 10/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 9/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 9/20 | 0.43 |
| ▸ | HDAC9 | Q9UKV0 | 9/20 | 0.43 |
| ▸ | HDAC5 | Q9UQL6 | 9/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2470461 | 0.99 | HDAC3 (0.45) | HDAC3HDAC6HDAC1HDAC4HDAC7 | |
| SCHEMBL2476650 | 0.97 | HDAC6 (0.41) | HDAC3HDAC6HDAC1HDAC4HDAC7 | |
| SCHEMBL15387150 | 0.87 | CNR2 (0.41) | — | |
| SCHEMBL2475030 | 0.87 | HCRTR1 (0.39) | — | |
| SCHEMBL8304298 | 0.85 | ATM (0.40) | — | |
| SCHEMBL2473403 | 0.84 | ATM (0.41) | — | |
| SCHEMBL2479313 | 0.84 | CXCR4 (0.40) | — | |
| SCHEMBL2476483 | 0.84 | CXCR4 (0.40) | — | |
| SCHEMBL2475712 | 0.83 | ATM (0.42) | — | |
| SCHEMBL2475170 | 0.83 | CNR2 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2374804-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | Genzyme Corporation (US) | 2011-10-12 | — | — | EP | claimed |
| US-7550484-B2 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | GENZYME CORPORATION (US) | 2009-06-23 | — | — | US | claimed |
| EP-2374804-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | Genzyme Corporation (US) | 2011-10-12 | — | — | EP | disclosed |
| US-20090281308-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | ANORMED, INC. (CA) | 2009-11-12 | — | — | US | disclosed |
| US-20090281308-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | ANORMED, INC. (CA) | 2009-11-12 | — | — | US | disclosed |
| US-7550484-B2 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | GENZYME CORPORATION (US) | 2009-06-23 | — | — | US | disclosed |
| US-7550484-B2 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | GENZYME CORPORATION (US) | 2009-06-23 | — | — | US | disclosed |
| US-7550484-B2 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | GENZYME CORPORATION (US) | 2009-06-23 | — | — | US | disclosed |
| US-7501518-B2 | Methods of making 2,6-diaryl piperidine derivatives | GENZYME CORPORATION (US) | 2009-03-10 | — | — | US | disclosed |
| US-7501518-B2 | Methods of making 2,6-diaryl piperidine derivatives | GENZYME CORPORATION (US) | 2009-03-10 | — | — | US | disclosed |
| US-7501518-B2 | Methods of making 2,6-diaryl piperidine derivatives | GENZYME CORPORATION (US) | 2009-03-10 | — | — | US | disclosed |
| US-20050154201-A1 | Methods of making 2,6-diaryl piperidine derivatives | ANORMED CORPORATION (CA) | 2005-07-14 | — | — | US | disclosed |
| US-20050059702-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | ANORMED CORPORATION (CA) | 2005-03-17 | — | — | US | disclosed |
| WO-2004093817-A2 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | ANORMED INC. (CA) | 2004-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154201-A1 | Methods of making 2,6-diaryl piperidine derivatives | ALDH7A1, DPYD, ALDH1A1 | HDAC3 1001/4885HDAC6 885/4885HDAC1 379/4885 |
| US-20050059702-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | CXCR4, CXCR1, CCR5 | HDAC3 2088/4885HDAC6 2280/4885HDAC1 1173/4885 |
| US-20090281308-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | CXCR4, CXCR1, CCR5 | HDAC3 2088/4885HDAC6 2280/4885HDAC1 1173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.